Pfizer is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. Founded in 1849, it develops and manufactures medicines and vaccines across multiple therapeutic areas.
AbbVie submitted an FDA NDA for tavapadon, a selective D1/D5 partial agonist for Parkinson's disease, after Phase 3 TEMPO trials showed improved motor scores and more 'on' time. It is a Cerevel asset.
The White House reports a 3.1% drop in prescription drug prices over the past year, the steepest decline since 1963, attributing it to President Trump's Most Favored Nation policies and TrumpRx discounts. Drugmakers like Pfizer have agreed to significant price cuts on several medications.
Valneva withdrew its U.S. BLA and IND for chikungunya vaccine Ixchiq after an FDA clinical hold tied to a serious adverse event. The company reported a wider FY2025 net loss of €115.2 million, while its Lyme vaccine VLA15 showed over 70% efficacy in Phase III.
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine for adults 50+. It was 27% more effective than standard flu shots in a large trial. The approval came after earlier FDA pushback.
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
China has become the dominant source of external drug innovation, with pharma licensing deals reaching $135.7 billion in 2025 and China developing 30% of the world's new innovative drugs. Meanwhile, India is expanding AI use in drug discovery and strengthening its CRDMO and IP infrastructure, though investment gaps persist.
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
Novartis AG is selling its 70.68% controlling stake in Novartis India to ChrysCapital for $175 million, triggering a mandatory open offer at INR 860.64 per share. Shares surged 20% as the Swiss drugmaker shifts investment to US manufacturing amid tariff risks.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07816471 |
RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed Adults |
ACTIVE_NOT_RECRUITING | |
| NCT07812467 |
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07798648 |
A Study of COVID-19 Vaccine(s) in Children and Adults |
NOT_YET_RECRUITING | PHASE3 |
| NCT07795736 |
Charactertizing Growth Hormone Deficiency in Traumatic Brain Injury |
RECRUITING | |
| NCT07794774 |
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07794761 |
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07794748 |
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults |
NOT_YET_RECRUITING | PHASE3 |
| NCT07792954 |
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE3 |
| NCT07792941 |
A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 |
RECRUITING | PHASE1 |
| NCT07783425 |
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema |
NOT_YET_RECRUITING | PHASE3 |
